- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Sun Pharma sees huge expansion opportunities in Punjab
Mohali: Sun Pharma today said it sees immense opportunities for expansion in Punjab even as its focus is on bringing Ranbaxy facilities to compliance.
"We have aggressive plans to grow not only in India but globally. We see huge opportunities for us to expand our manufacturing in Punjab and our facilities coming back in compliance when we are able to commercially exploit products for which company has made investments in the past," Sun Pharma MD Dilip Shanghvi said here while addressing Investors Summit today.
"It is a great blessing for us that post our acquisition of Ranbaxy, we have made significant investments in manufacturing in Punjab. Our prime focus is to bring facilities of Ranbaxy back to compliance so that these investments will start producing returns."
He also batted for investments in the state which creates employment and high quality jobs for the youth of country.
"We have aggressive plans to grow not only in India but globally. We see huge opportunities for us to expand our manufacturing in Punjab and our facilities coming back in compliance when we are able to commercially exploit products for which company has made investments in the past," Sun Pharma MD Dilip Shanghvi said here while addressing Investors Summit today.
"It is a great blessing for us that post our acquisition of Ranbaxy, we have made significant investments in manufacturing in Punjab. Our prime focus is to bring facilities of Ranbaxy back to compliance so that these investments will start producing returns."
He also batted for investments in the state which creates employment and high quality jobs for the youth of country.
Meghna A Singhania is the founder and Editor-in-Chief at Medical Dialogues. An Economics graduate from Delhi University and a post graduate from London School of Economics and Political Science, her key research interest lies in health economics, and policy making in health and medical sector in the country. She is a member of the Association of Healthcare Journalists. She can be contacted at meghna@medicaldialogues.in. Contact no. 011-43720751
Next Story